MannKind’s shares surged 24.1% following the quarter, driven by positive developments in its strategic partnership with United Therapeutics, clear regulatory progress for Afrezza Pediatrics, and encouraging early demand trends for FURO6 despite a seasonally soft Q1 revenue performance.

• Q1 revenues rose 15% year-over-year to $90 million, now including FURO6 contributions, though seasonally impacted by deductible resets causing lower fills and dose-per-prescription declines (~20% for FURO6 vs Q4).
• The expanded agreement with United Therapeutics brought an immediate $5 million payment and potential milestones totaling $35 million plus royalties, signaling validation of MannKind’s Technosphere platform.
• FURO6 demand indicators were positive, with record prescriber counts and a nearly 60% increase in doses dispensed through April compared to last year, suggesting momentum ahead of the Q3 auto-injector launch.
• Integration of SC Pharma is substantially complete, with identified synergies already exceeding the initial $20 million annual target, strengthening the company’s commercial infrastructure.
• FDA approval of an updated Afrezza label now includes clear dosing guidance to support the upcoming pediatric launch, positioned as a key near-term catalyst with a PDUFA date set for May 29.